Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

• Main Authors: Neeltje Steeghs (Author), Aaron R. Hansen (Author), Glenn J. Hanna (Author), Elena Garralda (Author), Haeseong Park (Author), James Strauss (Author), Michael Adam (Author), Gossett Campbell (Author), Jennifer Carver (Author), Rachael Easton (Author), Katherine Mays (Author), Peter Skrdla (Author), Herbert Struemper (Author), Michael L. Washburn (Author), Christopher Matheny (Author), Sarina A. Piha‐Paul (Author)
• Format: Book
• Published: Wiley, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract A phase I trial (NCT03447314; 204686) evaluated the safety and efficacy of GSK1795091, a Toll‐like receptor 4 (TLR4) agonist, in combination with immunotherapy (GSK3174998 [anti‐OX40 monoclonal antibody], GSK3359609 [anti‐ICOS monoclonal antibody], or pembrolizumab) in patients with solid t...